Boehringer Ingelheim presents late-stage data for chronic kidney disease treatment
Diabetes medicine Jardiance can slow the progression of chronic kidney disease while reducing the risk of cardiovascular death, finds a new study.
by christopher due karlsson, translated by daniel pedersen
On Friday, Boehringer Ingelheim publicized phase III data showing that empagliflozin, an SGLT2 inhibitor, has kidney and cardiovascular benefit for people with chronic kidney disease (CDK).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk to test diabetes tablet against Eli Lilly drug
For subscribers
Eli Lilly eyes unprecedented demand for Mounjaro
For subscribers
